Subject: Post Marketing Surveillance Study of ERLAMIDE®
Erlamide is an androgen receptor inhibitor containing Apalutamide 60 mg. This drug can be used for the management of metastatic castration sensitive prostate cancer and non-metastatic castration resistant prostate cancer.
Although every new products is marketed only after regulatory approval, it is important to know how it performs in day-to-day practice of individual medical practitioners. For this purpose, we have planed to conduct a retrospective study to assess the real-life performance of ERLAMIDE.
We invite you to participate in this study. All you need to do is to report on a standard format about your experience with ERLAMIDE in {{$numberOfPatient}} consecutive patients (to avoid any bias) in whom you prescribe this product in the normal course of your practice. Thus, this is not an experimental study because the product will be prescribed and purchased as you and your patients normally do.
If you agree to participate, you will need to provide some basic relevant information of these {{$numberOfPatient}} patients. Let us assure you that PMS form will not contain any information about patient’s demography as to ensure confidentiality.
As you will be spending some extra time to keep, copy and verify these {{$numberOfPatient}} patient’s record, we offer to pay you a total professional fee of Rs. {{$numberOfPatient}}/- on receiving details of {{$numberOfPatient}} patients.
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit, we hope you will provide consent to participate in this study. If you do, please sign and return the for our records.
|
}}){kind=logo}
}})